Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25969068 | 0.81 | FFAR4 (0.50) | FFAR4FFAR1PTGDRRBP4 | |
| SCHEMBL3813636 | 0.79 | PTGDR (0.57) | THRATHRBFFAR4FFAR1PTGDR2 | |
| SCHEMBL31661793 | 0.78 | THRA (0.67) | THRATHRBFFAR4FFAR1PTGDR | |
| SCHEMBL3055708 | 0.78 | THRA (0.67) | THRATHRBFFAR4FFAR1PTGDR | |
| SCHEMBL13678976 | 0.76 | PDE4B (0.39) | THRATHRBPTGDR | |
| SCHEMBL3813991 | 0.76 | FFAR4 (0.52) | FFAR4FFAR1 | |
| SCHEMBL28209378 | 0.76 | FFAR4 (0.55) | FFAR4FFAR1PTGDR | |
| SCHEMBL29786347 | 0.75 | HTR2C (0.52) | PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL20472535 | 0.75 | HTR2C (0.52) | PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL18361619 | 0.75 | PDE4B (0.50) | FFAR4FFAR1PARP15PARP10HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881958-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7485752-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1881958-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120125-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258740-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258740-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | THRA 2002/4885THRB 1382/4885FFAR4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.